133 related articles for article (PubMed ID: 27189164)
1. Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance.
Zhang H; Prado K; Zhang KX; Peek EM; Lee J; Wang X; Huang J; Li G; Pellegrini M; Chin AI
Clin Cancer Res; 2016 Nov; 22(21):5349-5361. PubMed ID: 27189164
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer.
Nordentoft I; Dyrskjøt L; Bødker JS; Wild PJ; Hartmann A; Bertz S; Lehmann J; Orntoft TF; Birkenkamp-Demtroder K
BMC Cancer; 2011 Apr; 11():135. PubMed ID: 21489314
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.
Pan J; Li X; Wu W; Xue M; Hou H; Zhai W; Chen W
Cancer Lett; 2016 Nov; 382(1):64-76. PubMed ID: 27591936
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells.
Zhang X; Taoka R; Liu D; Matsuoka Y; Tohi Y; Kakehi Y; Sugimoto M
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921102
[TBL] [Abstract][Full Text] [Related]
5. The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.
Zeng SX; Zhu Y; Ma AH; Yu W; Zhang H; Lin TY; Shi W; Tepper CG; Henderson PT; Airhart S; Guo JM; Xu CL; deVere White RW; Pan CX
Clin Cancer Res; 2017 Nov; 23(21):6580-6591. PubMed ID: 28808038
[No Abstract] [Full Text] [Related]
6. BMI1 activates P-glycoprotein via transcription repression of
Chen MK; Zhou JH; Wang P; Ye YL; Liu Y; Zhou JW; Chen ZJ; Yang JK; Liao DY; Liang ZJ; Xie X; Zhou QZ; Xue KY; Guo WB; Xia M; Bao JM; Yang C; Duan HF; Wang HY; Huang ZP; Qin ZK; Liu CD
Aging (Albany NY); 2021 Jul; 13(14):18310-18330. PubMed ID: 34270461
[TBL] [Abstract][Full Text] [Related]
7. VEGF-C inhibition reverses resistance of bladder cancer cells to cisplatin via upregulating maspin.
Zhu H; Yun F; Shi X; Wang D
Mol Med Rep; 2015 Aug; 12(2):3163-9. PubMed ID: 25936422
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer.
Lu CS; Shieh GS; Wang CT; Su BH; Su YC; Chen YC; Su WC; Wu P; Yang WH; Shiau AL; Wu CL
Oncotarget; 2017 May; 8(19):30844-30858. PubMed ID: 27244887
[TBL] [Abstract][Full Text] [Related]
9. A Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer.
Sun L; Lu J; Niu Z; Ding K; Bi D; Liu S; Li J; Wu F; Zhang H; Zhao Z; Ding S
PLoS One; 2015; 10(12):e0144484. PubMed ID: 26658059
[TBL] [Abstract][Full Text] [Related]
10. Histone Demethylase KDM7A Regulates Androgen Receptor Activity, and Its Chemical Inhibitor TC-E 5002 Overcomes Cisplatin-Resistance in Bladder Cancer Cells.
Lee KH; Kim BC; Jeong SH; Jeong CW; Ku JH; Kim HH; Kwak C
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781788
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer.
Grivas PD; Day KC; Karatsinides A; Paul A; Shakir N; Owainati I; Liebert M; Kunju LP; Thomas D; Hussain M; Day ML
Mol Med; 2013 Nov; 19(1):367-76. PubMed ID: 24166682
[TBL] [Abstract][Full Text] [Related]
12. Enzalutamide inhibits proliferation of gemcitabine-resistant bladder cancer cells with increased androgen receptor expression.
Kameyama K; Horie K; Mizutani K; Kato T; Fujita Y; Kawakami K; Kojima T; Miyazaki T; Deguchi T; Ito M
Int J Oncol; 2017 Jan; 50(1):75-84. PubMed ID: 27909718
[TBL] [Abstract][Full Text] [Related]
13. Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer.
Kerr M; Scott HE; Groselj B; Stratford MR; Karaszi K; Sharma NL; Kiltie AE
Clin Cancer Res; 2014 Nov; 20(21):5435-45. PubMed ID: 25224279
[TBL] [Abstract][Full Text] [Related]
14. Targeting an Autocrine Regulatory Loop in Cancer Stem-like Cells Impairs the Progression and Chemotherapy Resistance of Bladder Cancer.
Wang KJ; Wang C; Dai LH; Yang J; Huang H; Ma XJ; Zhou Z; Yang ZY; Xu WD; Hua MM; Lu X; Zeng SX; Wang HQ; Zhang ZS; Cheng YQ; Liu D; Tian QQ; Sun YH; Xu CL
Clin Cancer Res; 2019 Feb; 25(3):1070-1086. PubMed ID: 30397177
[TBL] [Abstract][Full Text] [Related]
15. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
[TBL] [Abstract][Full Text] [Related]
16. Forkhead Box R2 Knockdown Decreases Chemoresistance to Cisplatin via MYC Pathway in Bladder Cancer.
Li Y; Zu X; Hu X; Wang L; He W
Med Sci Monit; 2019 Nov; 25():8928-8939. PubMed ID: 31761897
[TBL] [Abstract][Full Text] [Related]
17. Foxp3 enhances HIF-1α target gene expression in human bladder cancer through decreasing its ubiquitin-proteasomal degradation.
Jou YC; Tsai YS; Lin CT; Tung CL; Shen CH; Tsai HT; Yang WH; Chang HI; Chen SY; Tzai TS
Oncotarget; 2016 Oct; 7(40):65403-65417. PubMed ID: 27557492
[TBL] [Abstract][Full Text] [Related]
18. The role of c-FLIP in cisplatin resistance of human bladder cancer cells.
Lee S; Yoon CY; Byun SS; Lee E; Lee SE
J Urol; 2013 Jun; 189(6):2327-34. PubMed ID: 23313194
[TBL] [Abstract][Full Text] [Related]
19. Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation.
Yoshino H; Enokida H; Osako Y; Nohata N; Yonemori M; Sugita S; Kuroshima K; Tsuruda M; Tatarano S; Nakagawa M
Mol Oncol; 2020 Sep; 14(9):2190-2202. PubMed ID: 32386122
[TBL] [Abstract][Full Text] [Related]
20. CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated.
Yin L; Liu S; Li C; Ding S; Bi D; Niu Z; Han L; Li W; Gao D; Liu Z; Lu J
Tumour Biol; 2016 Sep; 37(9):12731-12742. PubMed ID: 27448305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
